Velkommen til

Dansk Selskab for
Klinisk Cannabismedicin

Hvem er vi

Dansk selskab for Klinisk Cannabismedicin


Dansk Selskab for Klinisk Cannabismedicin (DSKCan) blev i 2022 stiftet som del af Lægevidenskabelige Selskaber under Lægeforeningen med det formål at afsøge mulighederne for anvendelse af cannabismedicin i patientbehandlingen og fremme evidensbaseret klinisk forskning inden for området.

Nyeste viden

Se mere
  • 8 jul
    Original: Seizure .

    Caregiver-reported non-seizure and seizure outcomes with cannabidiol and clobazam in patients aged ≥2 years with Lennox-Gastaut syndrome or Dravet syndrome: A subgroup analysis of the BECOME survey

    Purpose: This subgroup analysis of the BECOME (BEhavior, COgnition, and More with Epidiolex®) survey analyzed caregiver-reported seizure and non-seizure outcomes, including changes in caregiver burden, following cannabidiol (CBD) treatment in patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) aged ≥2 years taking concomitant clobazam, aligned with the European Medicines Agency indication. Methods: US-based caregivers of patients […]

    Læs mere
  • 8 jul
    Original: J Autism Dev Disord .

    Cannabidiol (CBD) Treatment for Severe Problem Behaviors in Autistic Boys: A Randomized Clinical Trial

    Open-label and observational studies suggest cannabidiol (CBD) reduces problematic behaviors in autistic children. No controlled clinical trials have addressed safety, tolerability, and efficacy. We conducted a double-blind, placebo-controlled crossover study of plant-derived CBD (Epidiolex®) to determine safety, tolerability, and behavior effects in autistic boys. Autistic boys with severe behavior problems age 7-14 years were randomized […]

    Læs mere
  • 8 jul
    Original: Journal of Pain and Symptom Management

    Barriers and Benefits of Subsidized Medical Cannabis in Oncologic Outpatient Palliative Care

    Outcomes 1. Participants will be able to analyze the role of subsidized medical marijuana in enhancing symptom control and quality of life for advanced cancer patients and its potential to reduce opioid use within outpatient palliative care settings. 2. Participants will be able to recognize and understand barriers such as financial access, patient knowledge, and […]

    Læs mere
  • 8 jul
    Original: Neurology®

    Safety, Tolerability, Pharmacokinetics, and Efficacy of Fenfluramine in Combination With Cannabidiol: Results From a Phase 1 Study

    Objective: To assess the safety, tolerability, pharmacokinetics, and efficacy of fenfluramine and cannabidiol in a small cohort of patients with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS). Background: DS and LGS are lifelong developmental and epileptic encephalopathies. Fenfluramine and cannabidiol are approved for the treatment of seizures in DS and LGS in the US and […]

    Læs mere